Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e326-

  Broos, Katrijn ^a   Van der Jeught, Kevin ^a   Puttemans, Janik ^a   Goyvaerts, Cleo ^a   Heirman, Carlo ^a   Dewitte, Heleen ^b   Verbeke, Rein ^b   Lentacker, Ine ^b   Thielemans, Kris ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

cytotoxic T lymphocyte; immunotherapy; liposome; mRNA; particle; type I interferon

Indexed keywords

ANTIGEN; CANCER VACCINE; INTERFERON; LIPID; LIPOFECTAMINE; MESSENGER RNA; OVALBUMIN; ENHANCED GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENCAPSULATION; FEMALE; IMMUNIZATION; IN VITRO GENE TRANSFER; IN VITRO STUDY; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; WART VIRUS; ANIMAL EXPERIMENT; CELL VIABILITY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOADSORPTION; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN EXPRESSION; RNA IMMUNIZATION;

EID: 85015248929     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.38     Document Type: Article

References (68)

1. 1 Benteyn, D, Heirman, C, Bonehill, A, Thielemans, K, Breckpot, K, mRNA-based dendritic cell vaccines. Expert Rev Vaccines 14 (2015), 161–176.
2. 2 Van Lint, S, Renmans, D, Broos, K, Dewitte, H, Lentacker, I, Heirman, C, et al. The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines 14 (2015), 235–251.
3. 3 Van Lint, S, Heirman, C, Thielemans, K, Breckpot, K, mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9 (2013), 265–274.
4. 4 Weide, B, Pascolo, S, Scheel, B, Derhovanessian, E, Pflugfelder, A, Eigentler, TK, et al. Direct injection of protamine-protected mRNA: results of a phase ½ vaccination trial in metastatic melanoma patients. J Immunother 32 (2009), 498–507.
5. 5 Goyvaerts, C, De Groeve, K, Dingemans, J, Van Lint, S, Robays, L, Heirman, C, et al. Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther 19 (2012), 1133–1140.
6. 6 Goyvaerts, C, Dingemans, J, De Groeve, K, Heirman, C, Van Gulck, E, Vanham, G, et al. Targeting of human antigen-presenting cell subsets. J Virol 87 (2013), 11304–11308.
7. 7 Goyvaerts, C, de Kurt, G, Van Lint, S, Heirman, C, Van Ginderachter, JA, De Baetselier, P, et al. Immunogenicity of targeted lentivectors. Oncotarget 5 (2014), 704–715.
8. 8 Ciré, S, Da Rocha, S, Yao, R, Fisson, S, Buchholz, CJ, Collins, MK, et al. Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo. PLoS One, 9, 2014, e101644.
9. 9 Van Lint, S, Goyvaerts, C, Maenhout, S, Goethals, L, Disy, A, Benteyn, D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72 (2012), 1661–1671.
10. 10 Kreiter, S, Selmi, A, Diken, M, Koslowski, M, Britten, CM, Huber, C, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70 (2010), 9031–9040.
11. 11 Perche, F, Benvegnu, T, Berchel, M, Lebegue, L, Pichon, C, Jaffrès, PA, et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7 (2011), 445–453.
12. 12 Zhou, WZ, Hoon, DS, Huang, SK, Fujii, S, Hashimoto, K, Morishita, R, et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther 10 (1999), 2719–2724.
13. 13 Martinon, F, Krishnan, S, Lenzen, G, Magné, R, Gomard, E, Guillet, JG, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23 (1993), 1719–1722.
14. 14 Pascolo, S, Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol, 2008, 221–235.
15. 15 Geall, AJ, Mandl, CW, Ulmer, JB, RNA: the new revolution in nucleic acid vaccines. Semin Immunol 25 (2013), 152–159.
16. 16 Van der Jeught, K, Bialkowski, L, Daszkiewicz, L, Broos, K, Goyvaerts, C, Renmans, D, et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget 6 (2015), 1359–1381.
17. 17 Phua, KK, Staats, HF, Leong, KW, Nair, SK, Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep, 4, 2014, 5128.
18. 18 Karikó, K, Buckstein, M, Ni, H, Weissman, D, Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005), 165–175.
19. 19 Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29 (2011), 154–157.
20. 20 Pollard, C, Rejman, J, De Haes, W, Verrier, B, Van Gulck, E, Naessens, T, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 21 (2013), 251–259.
21. 21 Karikó, K, Ni, H, Capodici, J, Lamphier, M, Weissman, D, mRNA is an endogenous ligand for toll-like receptor 3. J Biol Chem 279 (2004), 12542–12550.
22. 22 Devoldere, J, Dewitte, H, De Smedt, SC, Remaut, K, Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. Drug Discov Today 21 (2016), 11–25.
23. 23 Karikó, K, Muramatsu, H, Welsh, FA, Ludwig, J, Kato, H, Akira, S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16 (2008), 1833–1840.
24. 24 Hornung, V, Ellegast, J, Kim, S, Brzózka, K, Jung, A, Kato, H, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314 (2006), 994–997.
25. 25 Zeh, HJ 3rd, Perry-Lalley, D, Dudley, ME, Rosenberg, SA, Yang, JC, High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162 (1999), 989–994.
26. 26 Palmowski, MJ, Choi, EM, Hermans, IF, Gilbert, SC, Chen, JL, Gileadi, U, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168 (2002), 4391–4398.
27. 27 Ma, B, Zhang, S, Jiang, H, Zhao, B, Lv, H, Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release 123 (2007), 184–194.
28. 28 Sheng, Y, Yuan, Y, Liu, C, Tao, X, Shan, X, Xu, F, In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. J Mater Sci Mater Med 20 (2009), 1881–1891.
29. 29 Conner, SD, Schmid, SL, Regulated portals of entry into the cell. Nature 422 (2003), 37–44.
30. 30 Hansen, CG, Nichols, BJ, Molecular mechanisms of clathrin-independent endocytosis. J Cell Sci 122:Pt 11 (2009), 1713–1721.
31. 31 Sahay, G, Alakhova, DY, Kabanov, AV, Endocytosis of nanomedicines. J Control Release 145 (2010), 182–195.
32. 32 Jiang, W, Kim, BY, Rutka, JT, Chan, WC, Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3 (2008), 145–150.
33. 33 Dobrovolskaia, MA, Aggarwal, P, Hall, JB, McNeil, SE, Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5 (2008), 487–495.
34. 34 Yang, JP, Huang, L, Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA. Gene Ther 4 (1997), 950–960.
35. 35 Zelphati, O, Uyechi, LS, Barron, LG, Szoka, FC Jr, Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1390 (1998), 119–133.
36. 36 Simberg, D, Weisman, S, Talmon, Y, Faerman, A, Shoshani, T, Barenholz, Y, The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem 278 (2003), 39858–39865.
37. 37 Wasungu, L, Scarzello, M, van Dam, G, Molema, G, Wagenaar, A, Engberts, JB, et al. Transfection mediated by pH-sensitive sugar-based gemini surfactants; potential for in vivo gene therapy applications. J Mol Med (Berl) 84 (2006), 774–784.
38. 38 Dewitte, H, Verbeke, R, Breckpot, K, De Smedt, S, Lentacker, I, Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment. Nano Today 9 (2014), 743–758.
39. 39 Marchini, C, Montani, M, Amici, A, Amenitsch, H, Marianecci, C, Pozzi, D, et al. Structural stability and increase in size rationalize the efficiency of lipoplexes in serum. Langmuir 25 (2009), 3013–3021.
40. 40 Hoekstra, D, Rejman, J, Wasungu, L, Shi, F, Zuhorn, I, Gene delivery by cationic lipids: in and out of an endosome. Biochem Soc Trans 35:Pt 1 (2007), 68–71.
41. 41 Thiele, L, Diederichs, JE, Reszka, R, Merkle, HP, Walter, E, Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials 24 (2003), 1409–1418.
42. 42 Dewitte, H, Verbeke, R, Breckpot, K, Vandenbroucke, RE, Libert, C, De Smedt, SC, et al. Choose your models wisely: how different murine bone marrow-derived dendritic cell protocols influence the success of nanoparticulate vaccines in vitro. J Control Release 195 (2014), 138–146.
43. 43 Phua, KK, Nair, SK, Leong, KW, Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale 6 (2014), 7715–7729.
44. 44 Ciavarra, RP, Taylor, L, Greene, AR, Yousefieh, N, Horeth, D, van Rooijen, N, et al. Impact of macrophage and dendritic cell subset elimination on antiviral immunity, viral clearance and production of type 1 interferon. Virology 342 (2005), 177–189.
45. 45 Schaft, N, Wellner, V, Wohn, C, Schuler, G, Dörrie, J, CD8(+) T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?. Cancer Immunol Immunother 62 (2013), 1769–1780.
46. 46 Kastenmüller, K, Wille-Reece, U, Lindsay, RW, Trager, LR, Darrah, PA, Flynn, BJ, et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest 121 (2011), 1782–1796.
47. 47 Fuertes, MB, Kacha, AK, Kline, J, Woo, SR, Kranz, DM, Murphy, KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208 (2011), 2005–2016.
48. 48 Oh, JZ, Kurche, JS, Burchill, MA, Kedl, RM, TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 118 (2011), 3028–3038.
49. 49 Van der Jeught, K, Joe, PT, Bialkowski, L, Heirman, C, Daszkiewicz, L, Liechtenstein, T, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget 5 (2014), 10100–10113.
50. 50 Diken, M, Kreiter, S, Selmi, A, Britten, CM, Huber, C, Türeci, Ö, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 18 (2011), 702–708.
51. 51 Breckpot, K, Escors, D, Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets 9 (2009), 328–343.
52. 52 Yang, S, Linette, GP, Longerich, S, Haluska, FG, Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 169 (2002), 531–539.
53. 53 Viganò, S, Utzschneider, DT, Perreau, M, Pantaleo, G, Zehn, D, Harari, A, Functional avidity: a measure to predict the efficacy of effector T cells?. Clin Dev Immunol, 2012, 2012, 153863.
54. 54 Scheel, B, Teufel, R, Probst, J, Carralot, JP, Geginat, J, Radsak, M, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35 (2005), 1557–1566.
55. 55 Fotin-Mleczek, M, Duchardt, KM, Lorenz, C, Pfeiffer, R, Ojkić-Zrna, S, Probst, J, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34 (2011), 1–15.
56. 56 Van Lint, S, Thielemans, K, Breckpot, K, mRNA: delivering an antitumor message?. Immunotherapy 3 (2011), 605–607.
57. 57 Tan, PH, Beutelspacher, SC, Xue, SA, Wang, YH, Mitchell, P, McAlister, JC, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 105 (2005), 3824–3832.
58. 58 Breckpot, K, Escors, D, Arce, F, Lopes, L, Karwacz, K, Van Lint, S, et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 84 (2010), 5627–5636.
59. 59 Melero, I, Quetglas, JI, Reboredo, M, Dubrot, J, Rodriguez-Madoz, JR, Mancheño, U, et al. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12. Cancer Res 75 (2015), 497–507.
60. 60 Ceppi, M, Ruggli, N, Tache, V, Gerber, H, McCullough, KC, Summerfield, A, Double-stranded secondary structures on mRNA induce type I interferon (IFN alpha/beta) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J Gene Med 7 (2005), 452–465.
61. 61 Hervas-Stubbs, S, Perez-Gracia, JL, Rouzaut, A, Sanmamed, MF, Le Bon, A, Melero, I, Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17 (2011), 2619–2627.
62. 62 Nguyen, KB, Cousens, LP, Doughty, LA, Pien, GC, Durbin, JE, Biron, CA, Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 1 (2000), 70–76.
63. 63 Zhang, X, Sun, S, Hwang, I, Tough, DF, Sprent, J, Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8 (1998), 591–599.
64. 64 Nguyen, KB, Salazar-Mather, TP, Dalod, MY, Van Deusen, JB, Wei, XQ, Liew, FY, et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169 (2002), 4279–4287.
65. 65 Wang, Y, Swiecki, M, Cella, M, Alber, G, Schreiber, RD, Gilfillan, S, et al. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11 (2012), 631–642.
66. 66 Gautier, G, Humbert, M, Deauvieau, F, Scuiller, M, Hiscott, J, Bates, EE, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 201 (2005), 1435–1446.
67. 67 Byrnes, AA, Ma, X, Cuomo, P, Park, K, Wahl, L, Wolf, SF, et al. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur J Immunol 31 (2001), 2026–2034.
68. 68 Keyaerts, M, Verschueren, J, Bos, TJ, Tchouate-Gainkam, LO, Peleman, C, Breckpot, K, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 35 (2008), 999–1007.